EUVIMEDEUVIMED entdecken
Crossref

Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401)

Yoichiro Tohi, Akira Yokomizo, Takahiro Kimura, Masashi Wakabayashi, Masaki Shiota, Keiichiro Mori, Takuma Kato, Toyonori Tsuzuki, Masashi Kato, Keita Sasaki, Takashi Kawahara, Masatoshi Eto und 4 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02714-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yoichiro Tohi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Kagawa University, Kagawa 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan. Hauptthemen laut MEDLINE: Nomograms, Prostate-Specific Antigen, Prostatic Neoplasms, Salvage Therapy. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We have demonstrated that patients with prostate-specific antigen failure following radical prostatectomy benefit from salvage radiation therapy prior to salvage hormone therapy in a multicenter, randomized, open-label, phase 3 trial (JCOG0401). This study aimed to develop a nomogram to predict the efficacy of salvage radiation therapy in patients with prostate-specific antigen failure following radical prostatectomy. METHODS: This exploratory study focused on the salvage radiation therapy arm of the JCOG0401 trial and explored clinical factors that were significantly associated with the time to treatment failure of salvage radiation therapy using univariable and multivariable analyses. Based on these factors, we developed a nomogram to predict 3- and 5-year time to treatment failure. Discrimination and calibration of the nomogram were performed using concordance statistics and calibration plots. RESULTS: Ninety-six patients were included in the analysis, with a median time to treatment failure of 4.7 years. Multivariable Cox regression analysis identified pathological T stage ≥ 3, lack of lymph node dissection, lack of nerve-sparing, and prostate-specific antigen-doubling time < 6 months as significant factors associated with time to treatment failure (P < 0.05 for each). The nomogram including these factors achieved a concordance statistics of 0.6996. The hazard ratio for time to treatment failure was 2.946 (95% confidence interval 1.624-5.347), when the cut-off value of the nomogram was determined as the median nomogram score. CONCLUSIONS: The developed nomogram enables moderate prediction of the efficacy of salvage radiation therapy in patients with prostate-specific antigen recurrence following radical prostatectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NomogramsProstate-Specific AntigenProstatic NeoplasmsSalvage TherapyAgedHumansMaleMiddle AgedProstatectomyTreatment FailureSecondary Data AnalysisMulticenter Studies as TopicClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

NomogramPSA doubling timePSA failureProstate cancerProstatectomySalvage radiation therapy

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medicine, Kagawa University, Kagawa 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
  • Division of Urology, Harasanshin Hospital, Fukuoka, Japan.
  • Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
  • Japan Clinical Oncology Group Data Centre/Operations Office, National Cancer Centre Hospital, Tokyo, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Surgical Pathology, Aichi Medical University, Nagakute, Japan.

Förderung

  • National Cancer Center Research and Development Fund

Zitieren

APA

Tohi, Y., Yokomizo, A., Kimura, T., Wakabayashi, M., Shiota, M., Mori, K., Kato, T., Tsuzuki, T., Kato, M., Sasaki, K., Kawahara, T., Eto, M., Nishiyama, H., Kitamura, H., Sugimoto, M., & Urologic Oncology Study Group of Japan Clinical Oncology Group (2025). Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401). International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02714-4

Vancouver

Tohi Y, Yokomizo A, Kimura T, Wakabayashi M, Shiota M, Mori K, et al. Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401). International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02714-4

BibTeX
@article{Tohi2025,
  author = {Tohi, Yoichiro and Yokomizo, Akira and Kimura, Takahiro and Wakabayashi, Masashi and Shiota, Masaki and Mori, Keiichiro and Kato, Takuma and Tsuzuki, Toyonori and Kato, Masashi and Sasaki, Keita and Kawahara, Takashi and Eto, Masatoshi and Nishiyama, Hiroyuki and Kitamura, Hiroshi and Sugimoto, Mikio and Urologic Oncology Study Group of Japan Clinical Oncology Group, Urologic Oncology Study Group of Japan Clinical Oncology Group},
  title = {Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401)},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02714-4}
}
Kostenlos starten →